Viking Therapeutics (VKTX) Stock Forecast & Price Target
Score
Viking Therapeutics, Inc. price target
| VKTX | |
|---|---|
| Low | $34.00 |
| Average | $82.00 |
| High | $120.00 |
| Upside vs current price | +180.6% |
The average target of $82.00 is +180.6% versus the current VKTX price of $29.22.
Viking Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 5 |
| Buy | 14 |
| Hold | 2 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
21 analysts cover VKTX.
Viking Therapeutics, Inc. EPS and revenue estimates
VKTX shows the next fiscal years with at least three analysts: 2026 EPS $-5.32, 2027 EPS $-5.15. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-5.32 | $7.17M |
| 2027 | $-5.15 | $7.35M |
Is Viking Therapeutics, Inc. a buy or sell?
Of the 21 analysts covering Viking Therapeutics, Inc., 19 rate it a buy (5 strong buy and 14 buy), 2 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The VKTX consensus label is Buy, beside 19 buy-side ratings and 0 sell-side ratings.
The average target of $82.00 implies +180.6% versus the current price of $29.22.
Those 21 ratings on VKTX are a headcount, and the label on file is Buy.
Reading the Viking Therapeutics, Inc. forecast
The VKTX target range is wide: $34.00 at the low end, $82.00 in the middle, and $120.00 at the top.
Set next to the $29.22 VKTX quote, that average is +180.6%.
Ratings on the Viking Therapeutics, Inc. cluster: 19 of 21 analysts are on the buy side, 2 are at hold, and 0 are on the sell side, and the published consensus is Buy.
The average VKTX target over the last month is $59.50, below the $85.20 quarterly average.
21 analysts publish on VKTX, so one note does not swing the average by itself.
Viking Therapeutics, Inc. forecast questions
What is the VKTX price target?
The published range for VKTX is $34.00 to $120.00, with an average of $82.00. That average is +180.6% versus the current price of $29.22.
Is Viking Therapeutics, Inc. a buy or sell?
Of the 21 analysts covering Viking Therapeutics, Inc., 19 rate it a buy, 2 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the VKTX headcount is 19 buy, 2 hold, and 0 sell.
What is the EPS estimate for Viking Therapeutics, Inc.?
Analyst EPS estimates for Viking Therapeutics, Inc.: 2026 $-5.32, 2027 $-5.15.
What is the revenue estimate for Viking Therapeutics, Inc.?
Analyst revenue estimates for Viking Therapeutics, Inc.: 2026 $7.17M, 2027 $7.35M.
How many analysts cover VKTX?
21 analysts cover VKTX. Their consensus on VKTX is Buy, across those 21.